(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...
Civica will begin selling a type of insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s ...
Gov. Gavin Newsom says California will begin selling affordable insulin under its own label on Jan. 1, nearly three years ...
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, ...
LEHI, Utah, Oct. 16, 2025 /PRNewswire/ -- Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price ...
California is on track to become the first state to sell its own insulin. Santa Barbara County Health Pharmacy ...
BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...
California will offer CalRx-branded biosimilar insulin glargine pens for $11 per pen beginning January 1, 2026.
SACRAMENTO, California — California will start selling low-cost insulin in January, becoming the first state in the nation to ...
MedPage Today on MSN
OTC CGM at Walmart; California's Own Insulin; Ozempic's Price Negotiations Underway
In other news, Lilly announced its investigational oral GLP-1 agent orforglipron outperformed dapagliflozin (Farxiga) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback